Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Progestin-resistance is a main obstacle to the success of conservative therapy in type I young endometrial cancer patients. We have established a progestin-resistant endometrial cancer cell line by long-term induction with gradual increasing of progestin concentration. Our previous study confirmed that progestin activated PI3K/Akt pathway through a non-genomic pathway independent of Progesterone receptor (PR). Blocking PI3K pathway up-regulated PR expression and restored the anti-proliferative effect of medoxyprogesterone acetate (MPA) in progestin-resistant cells. We propose that PI3K/Akt activation may not be the only mechanism of progestin-resistance. To further explore other molecular events leading to progestin-resistance and to search for any possible approaches to reverse this resistance in endometrial cancer, we have characterized functional proteomics by reverse phase protein array (RPPA) in progestin-sensitive and -resistant endometrial cancer cells, and the RPPA results were confirmed by Western blots. Our results demonstrated up-regulation of Insulin-like growth factor-1 receptor (IGF-1R), and down-regulation of IGF binding protein 2 (IGFBP2) and Ataxia Telangiectasia (ATM) [an upstream molecule of adenosine monophosphate-activated kinase (AMPK) pathway] in progestin-resistant cells, suggesting that IGF/AMPK metabolic pathways are involved in progestin-resistance of endometrial cancer therapy. We further identified the differential effects of insulin stimulation on metabolic changes in progestin-sensitive and -resistant cell lines. We found that acute stimulation with high concentration of insulin not only activated PI3K/Akt, but also reduced the expression of PR, EGFR and IGF-1R, and further mediated proliferation of primary endometrial cancer cells. Continually stimulation with insulin reduced MPA-mediated anti-proliferation effect in progestin-sensitive cells, but no effect in progestin-resistant cells, indicating the existing of altered insulin-responsiveness in progestin-resistant cells. Furthermore, Metformin, an insulin-independent AMPK activator and is commonly used as an insulin sensitizer, could restore progestin sensitivity in progestin-resistant endometrial cancer cells. The restoration was demonstrated directly related to the inhibition of PI3K/Akt pathway, activation of AMPK and upregulation of PR transcription. In summary, our study revealed that PR/AMPK-IGF/PI3K network plays an important role on progestin-resistance in endometrial cancer therapy. The combinatory treatment of progestin with PI3K inhibitor, or with AMPK activator-metformin might be an effective conservative approach for endometrial cancer patients who developed progestin-resistance in their therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5755. doi:1538-7445.AM2012-5755

Epidermal Growth Factor Receptor Signaling Enhanced by Long-Term Medroxyprogesterone Acetate Treatment in Endometrial Carcinoma.

[Influence of Long-Term Treatment with MPA on the Biological Character of Endometrial Carcinoma Ishikawa Cell].

Role of Epidermal Growth Factor Receptor Signaling Pathway in Progestin Resistance of Human Endometrial Carcinoma Xenografts

Epidermal Growth Factor Receptor Signaling Pathway Involved in Progestin‐resistance of Human Endometrial Carcinoma: in a Mouse Model

Overexpressed Epidermal Growth Factor Receptor (egfr)‐induced Progestin Insensitivity in Human Endometrial Carcinoma Cells by the EGFR/mitogen‐activated Protein Kinase Signaling Pathway

Metformin Promotes Progesterone Receptor Expression Via Inhibition of Mammalian Target of Rapamycin (mtor) in Endometrial Cancer Cells

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

[Study of Mechanism of Medroxyprogesterone 17-Acetate on the Cancer Stem Cell-Like Properties of Human Endometrial Cancer].

Gefitinib Enhances Sensitivity of Endometrial Cancer Cells to Progestin Therapy Via Dual-Specificity Phosphatase 1.

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB

Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.

Over-expression EGFR reduced sensitivity of human endometrial carcinoma cells to progesterone

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

Abstract B009: Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets

Roles of SIRT1/FoxO1/SREBP-1 in the Development of Progestin Resistance in Endometrial Cancer

Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis

Pr/Ampk-Igf/Pi3k Network Plays A Major Role On Progestin-Resistance In Endometrial Cancer Therapy

Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line

Sterol Regulatory Element-Binding Protein–1/Fatty Acid Synthase Involvement in Proliferation Inhibition and Apoptosis Promotion Induced by Progesterone in Endometrial Cancer

Chronic Medroxyprogesterone Acetate (mpa) Treatment of Human Endometrial Stromal Cells Inhibits Chemokine Gene Expression.

In Vivo Assessment of the Regulation of Transforming Growth Factor Alpha, Epidermal Growth Factor (EGF), and EGF Receptor in the Human Endometrium by Medroxyprogesterone Acetate